The scientists found that between 2017 and 2022: Average total payments per patient increased 157% among adults without diabetes and 36% among those with diabetes Despite rising total payments, average out-of-pocket payments per patient declined 26% among adults without diabetes and 39% among those with diabetes GLP-1 use increased 643% among adults without diabetes and 230% among adults with diabetes Semaglutide became the dominant GLP-1 drug by 2022, accounting for 54% of usage among adults with diabetes and 65% among adults without diabetes The authors note that while this study only used data through 2022, Medicare and Medicaid spending on GLP-1s has continued to surge in recent years
License Suspension: DMV could suspend the license for 6 months to 1 year
Rimbaux S, Hommet C, Perrier D, Cottier JP, Legras A, Labarthe F, Lemarcis L, Autret A, Maillot F
Regulatory guidance from the Food & Drug Administration (FDA) and WHO emphasizes that proper aseptic technique, storage procedures, environmental controls, and documentation practices remain essential regardless of the presence of preservatives
.png.jpg)
